ReviewBioMed research international2014
Pharmacological strategies to prevent contrast-induced acute kidney injury.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Could Vitamin E Prevent Contrast-Induced Acute Kidney Injury? A Systematic Review and Meta-Analysis.Journal of Korean medical science · 2017Pooled it
- Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment.BMC nephrology · 2024Review
- Association of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and acute kidney disease in patients undergoing coronary angiography: a cohort study.International urology and nephrology · 2023Article
- A novel explainable online calculator for contrast-induced AKI in diabetics: a multi-centre validation and prospective evaluation study.Journal of translational medicine · 2023Article
- Assessment of Fasudil on Contrast-Associated Acute Kidney Injury Using Multiparametric Renal MRI.Frontiers in pharmacology · 2022Article
- Review
- Postcontrast Acute Kidney Injury After Transarterial Chemoembolization.Seminars in interventional radiology · 2021Review
- Use of Artificial Intelligence in Non-Oncologic Interventional Radiology: Current State and Future Directions.Digestive disease interventions · 2021Article
- Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches.Journal of translational medicine · 2020Review
- DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost-Utility Analysis.PharmacoEconomics - open · 2020Article
- N-acetylcysteine ameliorates contrast‑induced kidney injury in rats with unilateral hydronephrosis.Molecular medicine reports · 2018Article
- Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro.BioMed research international · 2017Article
- Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies).Annals of intensive care · 2016Review
- Resveratrol alleviates the cytotoxicity induced by the radiocontrast agent, ioxitalamate, by reducing the production of reactive oxygen species in HK-2 human renal proximal tubule epithelial cells in vitro.International journal of molecular medicine · 2016Article
- Histopathological Evaluation of Contrast-Induced Acute Kidney Injury Rodent Models.BioMed research international · 2016Review
- Resin from Virola oleifera Protects Against Radiocontrast-Induced Nephropathy in Mice.PloS one · 2015Article
- Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors.TheScientificWorldJournal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast-induced acute kidney injury (CI-AKI) is the most common iatrogenic cause of acute kidney injury after intravenous contrast media administration. In general, the incidence of CI-AKI is low in patients with normal renal function. However, the rate is remarkably elevated in patients with preexisting chronic kidney disease, diabetes mellitus, old age, high volume of contrast agent, congestive heart failure, hypotension, anemia, use of nephrotoxic drug, and volume depletion. Consequently, CI-AKI particularly in high risk patients contributes to extended hospitalizations and increases long-term morbidity and mortality. The pathogenesis of CI-AKI involves at least three mechanisms; contrast agents induce renal vasoconstriction, increase of oxygen free radicals through oxidative stress, and direct tubular toxicity. Several strategies to prevent CI-AKI have been evaluated in experimental studies and clinical trials. At present, intravascular volume expansion with either isotonic saline or sodium bicarbonate solutions has provided more consistent positive results and was recommended in the prevention of CI-AKI. However, the proportion of patients with risk still develops CI-AKI. This review critically evaluated the current evidence for pharmacological strategies to prevent CI-AKI in patients with a risk of developing CI-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.